-
FDA Approves Kesimpta, B-cell Targeting Therapy for Relapsing MS
Kesimpta (ofatumumab) was seen as superior to Aubagio in trials at lowering relapses and slowing disease progression, with comparable safety. Read more about it here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.